It can be a bit difficult to predict exactly what the big stories out of the JP Morgan Healthcare Conference are going to be. In 2019, it was the year’s biggest deal, Bristol-Myers Squibb’s acquisition of Celgene Corporation for $74 billion only days before the conference that became the talk of the meeting.
There’s no telling if some surprise deal will take the air out of the room, but here’s a look at some of the top presentations expected at the 38th annual JP Morgan Healthcare Conference taking place January 13-16 in San Francisco. With 12,000 attendees and 1,250 exhibitors from 155 countries, it’s safe to say there will be plenty of news, way too much to sum up in a single article, but here are some of the highlights.
Keynote speakers include Jamie Dimon, chief executive officer of JPMorgan Chase & Co., Ann C. Gallo, senior managing director and global industry analyst for Wellington Management, Sandra E. Peterson, partner with Clayton, Dubilier & Rice, Emma Walmsley, chief executive officer of GlaxoSmithKline, and Seema Verma, administrator of the U.S. Centers for Medicare and Medicaid Services (CMS).
The conference has suggested that one of the key themes of the meeting will be what the biopharmaceutical industry can look for in a U.S. presidential election year. So, drug pricing will undoubtedly be a hot topic, as will U.S. efforts to allow consumers to acquire drug from Canada, as well as efforts that have been made for the FDA to allow certain imports of drugs approved outside the U.S. but not by the FDA.
Literally hundreds of biopharma companies will be making presentations. Here are just a few:
Exelixis’ president and chief executive officer, Michael M. Morrissey, will provide a corporate overview on Tuesday, January 14 at 4:30 PM PST.
Intercept Pharmaceuticals’ president and chief executive officer Mark Pruzanski will make a presentation on Wednesday, January 15 at 10:00 AM PST followed by a breakout Q&A.
Theravance Biopharma’s executives will make a presentation on Wednesday, January 15 at 8:30 AM PST.
Sara Boyce, president and chief executive officer of Avidity Biosciences, will present an overview of the company’s approach to rare muscle disorders. The company recently closed on a successful $100 million Series C round. The presentation is Wednesday, January 15 at 10:30 AM PST.
Kodiak Sciences’ management will present a company overview on Tuesday, January 14 at 7:30 AM PST.
Stephane Bancel, chief executive officer of Moderna, will present an update on the company and its pipeline of mRNA programs on Monday, January 13, at 4:30 PST.
Those, of course, are just a small sampling of the numerous company presentations.